Sea Moss for Adult-Onset Still's Disease: Anti-Inflammatory, NLRP3 Inflammasome IL-1beta/IL-18 Autoinflammation & Mineral Support

Adult-onset Still's disease (AOSD) is a systemic autoinflammatory disorder driven by NLRP3/NLRP12 inflammasome hyperactivation with IL-1beta/IL-18 maturation via caspase-1, S100A8/S100A9 alarmins (calprotectin — serum marker), NF-kB/IL-6/IL-17/IFN-gamma amplification, macrophage activation syndrome (MAS) risk via perforin deficiency/hemophagocytosis, M2 macrophage IL-18 production, neutrophil NETosis and IL-8/CXCL8 recruitment; classic quotidian fever triad: salmon-pink evanescent rash (pathognomonic, appears during fever spikes), arthritis/arthralgia (wrists, knees — can be destructive), and spiking fever (>39°C, once or twice daily); other features: lymphadenopathy, hepatosplenomegaly, serositis (pleuritis, pericarditis), pharyngitis, leukocytosis (WBC >10k/mm3), elevated ferritin (>5x normal — marker); two clinical courses: monocyclic (single episode), polycyclic (recurrent), and chronic articular (RA-like destructive). Sea moss fucoidan modulates NF-kB, NLRP3 inflammasome, IL-1beta, IL-18, IL-6, NETosis; selenium supports macrophage GPx1 defense; omega-3 EPA/DHA modulates NLRP3 activating lipid mediators and resolvin D1; zinc supports S100A8/S100A9-related immune tolerance. NSAIDs first-line (fever/rash); prednisone moderate/severe; anakinra/canakinumab (IL-1 blockade — most effective); tocilizumab (IL-6R); JAK inhibitors (baricitinib/ruxolitinib) for refractory; IVIG/cyclosporine for MAS.

Read the full guide